Acessibilidade / Reportar erro

O zinco no tratamento de degeneração hepatolenticular a propósito de três casos: three case reports

Oral zinc therapy in hepatolenticular degeneration

Resumos

São descritos três casos d© degeneração hepatolenticular (DHL.) em que o efeito nefrotóxico da D-penicilina (DP) levou à substituição dessa droga por zinco, com resultados satisfatórios. O tempo médio de tratamento com zinco nos casos descritos foi de 2 anos e 7 meses. Com base nos dados de literatura e na experiência com esses pacientes, os autores consideram que os sais de zinco podem ser uma alternativa para o tratamento da DHL quando a DP determina o aparecimento de efeitos colaterais graves que levam à sua retirada definitiva.

degeneração hepatolenticular; terapêutica; zinco


Three patients with symptoms and signs of hepatolenticular degeneration (HLD) who developed serious renal side effects of D-penicillamine (DP) had their therapeutic schedule changed to zinc. Patient 1, a 55 year-old man had been well until 12 years old, when skeletal changes (osteomalacia) due to tubular renal disturbance began. His diagnosis of HLD had first been established at age of 32 when he presented with «wing-beat» tremor. He was then begun on DP and his neurological symptons resolved within one year of initiating therapy but skeletal abnormalities remained unchanged as a sequel. During the next 22 years the patient was continued on DP therapy but with poor compliance. Then the reapperance of his neurological manifestations occurred several times. By the age of 53, after one year without therapy, his neurological status has worse. DP was reinstituted but some weeks later his renal laboratorial parameters became serevely affected. DP was discontinued and zinc sulfate (220mg three times daily) was introduced. On this therapeutic regimen his renal laboratorial parameters returned to previous level after one month. Within one year on this therapeutic regimen neurological manifestations were resolved. After 31 months on zinc treatment he remains neurologically asymptomatic and his renal function is satisfactory. Patient 2, a 41 years old woman had been her diagnosis of HLD at age of 20, when following the diagnosis of the disease in her old brother, she was found to have the laboratorial features of HLD and bilateral Kayser-Fleischer rings. DP treatment was recommended at that time but she quitted the follow-up. When she. was 23, an esophageal variceal bleeding occurred. At the age of 30 she started DP treatment. During 9 years the patient, under regular use of the drug remained assymptomatic. At the age of 39 she developed acute renal failure due to penicillamine-induced immune complex nephropathy. DP was then stopped and prednisone introduced. After 4 months, as renal function returned to normal, prednisone was discontinued and zinc sulphate (220mg three times daily) introduced. She remained asymptomatic for 38 months. By the age of 41 a relapse of renal manifestations occurred, and she died months later. Patient 3, a 20 year-old man developed hemolytic anemia as the single manifestation of HLD at 16. DP was introduced with excellent results. Neverthless, 4 months later, with the appearance of severe renal side--effects, this drug was replaced by zinc sulphate (220mg three times daily). After 11 months under this therapeutic schedule he was hematologically asymptomatic but an epigastric distress appeared. Zinc sulphate was discontinued and zinc acetate (170mg three times daily) was introduced. Since that time, after 30 months of treatment with zinc, he remains asymptomatic and Kayser-Fleisher rings disappeared. A review of zinc salts therapy of HLD is presented and discussed.

hepatolenticular degeneration; therapeutics; zinc


O zinco no tratamento de degeneração hepatolenticular a propósito de três casos

Oral zinc therapy in hepatolenticular degeneration: three case reports

Egberto R. BarbosaI; Emmanuel de Almeida BurdmannI; Eduardo R. CançadoI; Mônica S. HaddadII; M. ScaffIII; Horacio M. CanelasIII

IMédico Assistente. Trabalho do Grupo de Estudo de Distúrbios do Movimento da Divisão de Clínica Neurológica (DCN), Disciplina de Nefrologia e Disciplina de Gastroenterologia do Hospital das Clínicas (HC) da Faculdade de Medicina da Universidade de São Paulo (FMUSP)

IIMédica Residente. Trabalho do Grupo de Estudo de Distúrbios do Movimento da Divisão de Clínica Neurológica (DCN), Disciplina de Nefrologia e Disciplina de Gastroenterologia do Hospital das Clínicas (HC) da Faculdade de Medicina da Universidade de São Paulo (FMUSP)

IIIProfessor Titular. Trabalho do Grupo de Estudo de Distúrbios do Movimento da Divisão de Clínica Neurológica (DCN), Disciplina de Nefrologia e Disciplina de Gastroenterologia do Hospital das Clínicas (HC) da Faculdade de Medicina da Universidade de São Paulo (FMUSP)

RESUMO

São descritos três casos d© degeneração hepatolenticular (DHL.) em que o efeito nefrotóxico da D-penicilina (DP) levou à substituição dessa droga por zinco, com resultados satisfatórios. O tempo médio de tratamento com zinco nos casos descritos foi de 2 anos e 7 meses. Com base nos dados de literatura e na experiência com esses pacientes, os autores consideram que os sais de zinco podem ser uma alternativa para o tratamento da DHL quando a DP determina o aparecimento de efeitos colaterais graves que levam à sua retirada definitiva.

Palavras chave: degeneração hepatolenticular, terapêutica, zinco.

SUMMARY

Three patients with symptoms and signs of hepatolenticular degeneration (HLD) who developed serious renal side effects of D-penicillamine (DP) had their therapeutic schedule changed to zinc. Patient 1, a 55 year-old man had been well until 12 years old, when skeletal changes (osteomalacia) due to tubular renal disturbance began. His diagnosis of HLD had first been established at age of 32 when he presented with «wing-beat» tremor. He was then begun on DP and his neurological symptons resolved within one year of initiating therapy but skeletal abnormalities remained unchanged as a sequel. During the next 22 years the patient was continued on DP therapy but with poor compliance. Then the reapperance of his neurological manifestations occurred several times. By the age of 53, after one year without therapy, his neurological status has worse. DP was reinstituted but some weeks later his renal laboratorial parameters became serevely affected. DP was discontinued and zinc sulfate (220mg three times daily) was introduced. On this therapeutic regimen his renal laboratorial parameters returned to previous level after one month. Within one year on this therapeutic regimen neurological manifestations were resolved. After 31 months on zinc treatment he remains neurologically asymptomatic and his renal function is satisfactory. Patient 2, a 41 years old woman had been her diagnosis of HLD at age of 20, when following the diagnosis of the disease in her old brother, she was found to have the laboratorial features of HLD and bilateral Kayser-Fleischer rings. DP treatment was recommended at that time but she quitted the follow-up. When she. was 23, an esophageal variceal bleeding occurred. At the age of 30 she started DP treatment. During 9 years the patient, under regular use of the drug remained assymptomatic. At the age of 39 she developed acute renal failure due to penicillamine-induced immune complex nephropathy. DP was then stopped and prednisone introduced. After 4 months, as renal function returned to normal, prednisone was discontinued and zinc sulphate (220mg three times daily) introduced. She remained asymptomatic for 38 months. By the age of 41 a relapse of renal manifestations occurred, and she died months later. Patient 3, a 20 year-old man developed hemolytic anemia as the single manifestation of HLD at 16. DP was introduced with excellent results. Neverthless, 4 months later, with the appearance of severe renal side--effects, this drug was replaced by zinc sulphate (220mg three times daily). After 11 months under this therapeutic schedule he was hematologically asymptomatic but an epigastric distress appeared. Zinc sulphate was discontinued and zinc acetate (170mg three times daily) was introduced. Since that time, after 30 months of treatment with zinc, he remains asymptomatic and Kayser-Fleisher rings disappeared. A review of zinc salts therapy of HLD is presented and discussed.

Key words: hepatolenticular degeneration, therapeutics, zinc.

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

Dr. Egberto Reis Barbosa — Clínica Neurológica, Hospital das Clínicas, FMUSP - Caixa Postal 3461 - 01060 São Paulo SP - Brasil.

  • 1. Barbosa ER. Degeneração hepatolenticular: aspectos clínicos e laboratoriais de 89 casos. Dissertação de Mestrado. Faculdade de Medicina, da Universidade de São Paulo. São Paulo, 1983.
  • 2. Barbosa ER. Degeneração hepatolenticular: aspectos terapêuticos em 76 casos. Tese de Doutorado. Faculdade de Medicina, Universidade de São Paulo. São Paulo, 1990.
  • 3. Brewer GJ. Zinc therapy of Wilson's disease: two views. Hepathology 1986, 6:1047-1048.
  • 4. Brewer GJ, Hill GM, Dick RD, Nostrant TT, Sams JS, Wells JJ, Prasad AS. Treatment of Wilson's disease with zinc: III Prevention of reaccumulation of hepatic copper. J Lab Clin Med 1987. 109:526-531.
  • 5. Brewer GJ, Hill GM. Prasad AS, Cossack ZT, Rabanni P. Oral zinc the rapy for Wilson s disease. Ann Intern Med 1983, 99:314-320.
  • 6. Brewer GJ, Terry CA, Aisen AM, Gretchen MH. Worsening of neurologic syndrome in patient with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987, 44:490-493.
  • 7. Caillie-Bertrand M. Degenhart HJ, Visser HKA, Sinnaasappel M, Bouquet J. Oral zinc sulphate for Wilson's disease. Arch Dis Child 1985, 60:656-659.
  • 8. Canelas HM. Degeneração hepatolenticular: a propósito de 102 casos. Arq Neuropsiquiat 1987, 197-212.
  • 9. Hill GM. Brewer GJ. Juni JE, Prasad AS, Dick RD. Treatment of Wilson's disease with zinc: H. Validation of oral copper 64 with copper balance. Am J Med Sci 1986, 292:344-349.
  • 10. Hill GM, Brewer GJ, Prasad AS, Hydrick R, Hartmann DE. Treatment of Wilson's disease with zinc. I: Oral zinc therapy regimens. Hepatology 1987, 7:522-528.
  • 11. Hoffman HN, Phyliky RL, Fleming CR. Zinc-induced copper deficiency. Gastroenterology 1988, 94:508-512.
  • 12. Hoogenraad TU, van der Hamer CJA. Three years of continuous oral zinc therapy in 4 patients with Wilson' disease. Acta Neurol Scand 1983, 67:356-364.
  • 13. Hoogenraad TU, van der Hamer CJA, van Hattum J. Effective treatment of Wilson's disease with oral zinc sulphate: two case reports. Br Med J, 1984, 289:273-276.
  • 14. Hoogenraad TU, van der Hamer CJA, Koevoet R, Ruyter Korver EGWM. Oral zinc in Wilson's disease. Lancet 1978, 2:1262.
  • 15. Hoogenraad TU, van Hattum J. Unithiol in Wilson's disease. Br Med J, 1985, 290:1213.
  • 16. Hoogenraad TU, van Hattum J, van der Hamer CJA. Management of Wilson's disease with zinc sulphate: experience in a series of 27 patients. J Neurol Sci 1987, 77:137-146.
  • 17. Hoogenraad TU, Koevoet R, Ruyter EGWM. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration) Eur Neurol 1979, 18:205-211.
  • 18. Hoogenraad TU, Rothhuizen J. Compliance in Wilson's disease and in copper toxicosis of Bedlington terriers. Lancet 1986, 2:170.
  • 19. Lipsky MA, Golian JJ. Treatment of Wilson's disease: in D-penicillamine we trust what about zinc? Hepatology 1987, 7:593-595.
  • 20. Prasad AS, Brewer GJ, Schoomaker EB, Rabbani P. Hypocupremia induced by zinc therapy in adults. J Am Med Ass 1978, 240:2166-2168.
  • 21. Scheinberg IH. Zinc therapy of Wilson's disease: two views. Hepatology 1986, 6:1038-1049.
  • 22. Scheinberg IH, Sternlieb I, Schilsky M, Stockert RJ. Penicillamine may detoxity copper in Wilson's disease. Lancet 1987, 2:95.
  • 23. Schouwink G. De hepato-cerebrale degeneratie met een onderzoek van de zinkstof-wisseling. Thesis. Van der Wiel, Arnhem, 1961. English Abstract.
  • 24. Smith SE, Larson EJ. Zinc toxicity in rats: antagonistic effects of copper on liver. J Biol Chem 1946, 163:29-38.
  • 25. Walshe JM. Treatment of Wilson's disease with zinc sulphate. Br Med J 1984, 289:558-559.

Datas de Publicação

  • Publicação nesta coleção
    22 Fev 2011
  • Data do Fascículo
    Mar 1992
Academia Brasileira de Neurologia - ABNEURO R. Vergueiro, 1353 sl.1404 - Ed. Top Towers Offices Torre Norte, 04101-000 São Paulo SP Brazil, Tel.: +55 11 5084-9463 | +55 11 5083-3876 - São Paulo - SP - Brazil
E-mail: revista.arquivos@abneuro.org